Comparative Evaluation of the ViroSeq™ HIV-1 Genotyping System and an In-House Method for Analysis of HIV-1 Drug-Resistance Mutations in China

被引：0

作者：

Xu, Sihong ^{[1
]}

Zhong, Ping ^{[2
]}

Li, Jingyun ^{[3
]}

Song, Aijing ^{[1
]}

Li, Hanping ^{[3
]}

Nie, Jianhui ^{[1
]}

Li, Xiuhua ^{[1
]}

Wang, Youchun ^{[1
]}

机构：

[1] Natl Inst Control Pharmaceut & Biol Prod, Dept Cell Biol, Beijing 100050, Peoples R China

[2] Shanghai Ctr Dis Prevent & Control, Shanghai, Peoples R China

[3] Acad Mil Med Sci, Ctr AIDS, Inst Microbiol & Epidemiol, Beijing, Peoples R China

来源：

MOLECULAR DIAGNOSIS & THERAPY | 2011年 / 15卷 / 01期

关键词：

IMMUNODEFICIENCY-VIRUS TYPE-1; SEQUENCE-BASED ANALYSIS; TREATMENT-NAIVE; CIRCULATING RECOMBINANT; PLASMA SAMPLES; THERAPY; PERFORMANCE; PREVALENCE; SENSITIVITY; STRAINS;

D O I：

10.1007/BF03257192

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Background and Objective: With the introduction of the ViroSeq (TM) HIV-1 Genotyping System (ViroSeq (TM) assay) into China, it is important to evaluate the impact of the diversity of HIV-1 genotypes found in China on the performance of the ViroSeq (TM) assay compared with an in-house method. Materials and Methods: A total of 318 plasma samples, collected from 206 HIV-1-infected patients receiving antiretroviral therapy and 112 treatment-naive HIV-1-infected patients, were used for evaluating the concordance of genotypes, genotypic resistance mutations, and phenotypic resistance between the ViroSeq (TM) assay and an in-house method for analyzing HIV-1 drug resistance in China. Results: A concordance of genotypes between the ViroSeq (TM) assay and the in-house method was observed for the 313 samples (98.4%), using the Stanford University HIV Drug Resistance Database (Version 6.0.5). The overall concordances of drug-resistance-related mutations (DRRMs) in the HIV-1 protease (PR) and reverse transcriptase (RT) coding sequences within the HIV-1 pol gene, scored by the ViroSeq (TM) assay and the in-house method, were 99.5% and 98.1%, respectively. Discrepancies between the two methods were found in 38 samples assayed for protease inhibitor (PI) DRRMs, 36 samples assayed for nucleoside reverse transcriptase inhibitor (NRTI) DRRMs, and 72 samples assayed for non-nucleoside reverse transcriptase inhibitor (NNRTI) DRRMs, and 100%, 88.9%, and 87.5% of the samples with discrepancies for PI, NRTI, and NNRTI DRRMs, respectively, were genotyped as subtype B. One NNRTI mutation (the RT mutation Y318F) was reported only by the ViroSeq (TM) assay, and this discrepancy resulted from the difference in the pol gene lengths generated by the two systems. Furthermore, the overall concordance of phenotypic resistance was 94.7% (301/318) between the two methods. Conclusion: The ViroSeq (TM) assay will be a useful tool for monitoring clinical drug resistance and for better management of HIV-1 patients receiving antiretroviral therapy in China.

引用

页码：41 / 52

页数：12

共 36 条

[1]

*ABB LAB, 2007, VIROSEQ V2 7 INSTR U, P50

[2]

BABAFEMI T, 2009, INT J INFECT DIS, V13, P552

[3] A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy [J].

Baxter, JD ;

Mayers, DL ;

Wentworth, DN ;

Neaton, JD ;

Hoover, ML ;

Winters, MA ;

Mannheimer, SB ;

Thompson, MA ;

Abrams, DI ;

Brizz, BJ ;

Ioannidis, JPA ;

Merigan, TC .

AIDS, 2000, 14 (09) :F83-F93

[4] Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping [J].

Chen, J. H. K. ;

Wong, K. H. ;

Chan, K. ;

Lam, H. Y. ;

Lee, S. S. ;

Li, P. ;

Lee, M. P. ;

Tsang, D. N. ;

Zheng, B. J. ;

Yuen, K. Y. ;

Yam, W. C. .

JOURNAL OF CLINICAL VIROLOGY, 2007, 39 (02) :125-131

[5] Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D [J].

Church, Jessica D. ;

Jones, Dana ;

Flys, Tamara ;

Hoover, Donald ;

Marlowe, Natalia ;

Chen, Shu ;

Shi, Chanjuan ;

Eshleman, James R. ;

Guay, Laura A. ;

Jackson, J. Brooks ;

Kumwenda, Newton ;

Taha, E. Taha ;

Eshleman, Susan H. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (04) :430-432

[6] Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-I) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples [J].

Cunningham, S ;

Ank, B ;

Lewis, D ;

Lu, W ;

Wantman, M ;

Dileanis, J ;

Jackson, JB ;

Palumbo, P ;

Krogstad, P ;

Eshleman, SH .

JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (04) :1254-1257

[7] Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations [J].

Demeter, L ;

Haubrich, R .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 :S3-S9

[8] Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].

Durant, J ;

Clevenbergh, P ;

Halfon, P ;

Delgiudice, P ;

Porsin, S ;

Simonet, P ;

Montagne, N ;

Boucher, CAB ;

Schapiro, JM ;

Dellamonica, P .

LANCET, 1999, 353 (9171) :2195-2199

[9] Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer [J].

Eshleman, SH ;

Crutcher, G ;

Petrauskene, O ;

Kunstman, K ;

Cunningham, SP ;

Trevino, C ;

Davis, C ;

Kennedy, J ;

Fairman, J ;

Foley, B ;

Kop, J .

JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (02) :813-817

[10] Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-base analysis of diverse human immunodeficiency virus type 1 strains [J].

Eshleman, SH ;

Hackett, J ;

Swanson, P ;

Cunningham, SP ;

Drews, B ;

Brennan, C ;

Devare, SG ;

Zekeng, L ;

Kaptué, L ;

Marlowe, N .

JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (06) :2711-2717

← 1 2 3 4 →